MYH3 and non-Hodgkin lymphoma: Our study, supporting the use of five approaches, including TMT, gene ontology (GO), Reactome, KEGG pathway, and molecular docking analyses, suggests that DEPs, Myh3, Eno2, and H4c11 may be three novel biomarkers or therapeutic targets for non-Hodgkin lymphoma.